A widely used and affordable medication for gout might also help reduce heart attacks and strokes in people with heart ...

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

A new study published in The Journal of Rheumatology showed that despite using lower dosages, febuxostat more successfully ...

Although rates vary widely between countries, the total number of young people with the condition is expected to continue rising through 2035.

Gout is the most common form of inflammatory arthritis, with worldwide prevalence of approximately four%. The accumulation of ...

Sobi agrees to buy Arthrosi Therapeutics for up to $1.5 billion, adding the Phase 3 gout asset pozdeutinurad to expand its ...

The burden of cardiovascular-kidney-metabolic (CKM) comorbidities among adults with gout is high, noted Chio Yokose, MD, MSc, ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of a Phase II clinical trial ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi ...